Persistent Fetal Vasculature: Mechanisms of Development, Current Treatment Approaches, and Advancements in Therapy

By
Robert H. Henderson
October 6, 2026

Overview

Persistent fetal vasculature (PFV) is a developmental ocular disorder caused by incomplete regression of the fetal hyaloid vascular system, with anterior, posterior, or combined manifestations. The supplied material describes coordinated roles for VEGF withdrawal, macrophage-mediated apoptosis, Wnt signalling, and ocular neurodevelopment; it also highlights the need to distinguish PFV from retinoblastoma and related vitreoretinopathies. In a registry analysis of unilateral PFV-associated cataract surgery, 10% achieved age-normal visual acuity at five years, while glaucoma-related adverse events were reported in aphakic PFV eyes.

Background

The condition was first described as persistent hyperplastic primary vitreous and later reframed as persistent fetal vasculature to encompass a continuum of anterior and posterior findings. PFV findings occur in approximately 20–45% of unilateral and 5–10% of bilateral congenital cataract cases in surgical series. Bilateral presentations may be associated with systemic or genetic conditions, including Norrie disease and familial exudative vitreoretinopathy. Because PFV can present as infantile leukocoria and mimic retinoblastoma, accurate clinical assessment is important.

Data Highlights

Measure	Finding	Source context
PFV findings in congenital cataract surgical series	Approximately 20–45% of unilateral cases; approximately 5–10% of bilateral cases	Article context
Age-normal visual acuity at five years after lensectomy	10% (95% CI, 3%–23%)	PEDIG registry analysis of unilateral PFV-associated cataract
Glaucoma-related adverse events in aphakic PFV eyes	Cumulative incidence 24% (95% CI, 9%–37%)	PEDIG registry analysis
Glaucoma-related event hazard in infants aged ≤1 year at lensectomy	No significant difference between PFV and non-PFV aphakic eyes	PEDIG registry analysis

Key Findings

PFV represents incomplete involution of the fetal hyaloid vascular system and may involve anterior, posterior, or combined ocular structures.
During normal development, increasing oxygen tension reduces HIF activity and VEGF production, withdrawing endothelial survival signals and contributing to hyaloid regression.
Experimental work cited in the article identifies macrophage-derived WNT7b and β-catenin-dependent signalling, including the p53–Arf–SMAD2/3 pathway, as contributors to endothelial apoptosis and vascular regression.
Disruption of NDP, FZD4, LRP5, or TSPAN12 signalling is associated in animal models with retinal hypovascularity, falciform retinal folds, and persistence of the hyaloid artery; related human disorders include Norrie disease and FEVR.
Biallelic loss-of-function variants in ATOH7 have been associated with autosomal-recessive PFV featuring microphthalmia, persistent hyaloid vasculature, and optic-nerve hypoplasia.
In the PEDIG registry analysis of unilateral PFV-associated cataract, 10% achieved age-normal visual acuity five years after lensectomy; glaucoma-related adverse events had a 24% cumulative incidence in aphakic PFV eyes.

Clinical Implications

The source describes PFV as an important cause of infantile leukocoria that can mimic retinoblastoma, requiring careful diagnostic discrimination. It also states that management involves assessing whether surgery may benefit the eye or instead accelerate loss of structure and comfort; the reported five-year surgical outcomes include limited age-normal visual acuity and glaucoma-related adverse events.

Conclusion

PFV reflects disrupted coordination among angiogenic signalling, programmed vascular regression, and ocular development. The supplied clinical and registry information emphasizes its variable phenotype, genetic overlap with inherited vitreoretinopathies, and the need to weigh potential surgical benefit against reported outcomes and complications.